TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7575051

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine polacrilex
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine polacrilex
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (0.5 mg nicotine polacrilex)
Number of subjects: 90
Study: 2318962

Group type: EXPERIMENTAL
Intervention: Intradermal inoculation of antigen-antibody complexes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7189144

Group type: EXPERIMENTAL
Intervention: Soybean proteins and pectins (EMD 35327)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional 1000 kcal mixed diet
Number of subjects: 20
Study: 30471383

Group type: EXPERIMENTAL
Intervention: Competitive learning environment (paired learning)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-competitive learning environment (alone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both competitive and non-competitive learning environments
Number of subjects: 16
Study: 27603790

Group type: EXPERIMENTAL
Intervention: Egregious security breach
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Station topic
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 25986643

Group type: EXPERIMENTAL
Intervention: Educational intervention among occupational physicians to enhance the initiation of work modifications
Number of subjects: 0
Study: 23729801

Group type: EXPERIMENTAL
Intervention: Ofatumumab 0.3 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ofatumumab 3 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ofatumumab 30 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ofatumumab 60 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ofatumumab 100 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 21727276

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1195
Study: 19398651

Group type: EXPERIMENTAL
Intervention: PF‐00489791 10 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: PF‐00489791 20/40 mg
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 16731075

Group type: EXPERIMENTAL
Intervention: Fast-absorbing polyglactin 910
Number of subjects: 192

Group type: COMPARATOR
Intervention: Chromic catgut
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard polyglactin 910
Number of subjects: 192
Study: 15885525

Group type: EXPERIMENTAL
Intervention: Integrated dual disorders treatments
Number of subjects: 152
Study: 12094756

Group type: EXPERIMENTAL
Intervention: Proportional hazards models with random effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequentist approach - penalized maximum likelihood method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian approach - Gibbs sampling method
Number of subjects: 0
Study: 10088066

Group type: EXPERIMENTAL
Intervention: Captopril (up to 75 mg/day)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Metoprolol (up to 200 mg/day)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Captopril + Metoprolol
Number of subjects: 250

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 250

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 250
Study: 7769900

Group type: EXPERIMENTAL
Intervention: Supplemented formula with fish oil (DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 0
Study: 2138051

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cilazapril (1.25 mg/day and 5.0 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6772293

Group type: EXPERIMENTAL
Intervention: VAC plus adriamycin (Regimen I)
Number of subjects: 193

Group type: COMPARATOR
Intervention: VAC alone (Regimen II)
Number of subjects: 193

Group type: COMPARATOR
Intervention: VAC and bilateral pulmonary irradiation (Regimen III)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Bilateral pulmonary irradiation for subclinical disease
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Adriamycin added to VAC chemotherapy
Number of subjects: 193
Study: 30522875

Group type: EXPERIMENTAL
Intervention: Suvorexant 20/15 mg
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Suvorexant 40/30 mg
Number of subjects: 1824

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 1824
Study: 29202801

Group type: EXPERIMENTAL
Intervention: Screening for anxiety and depression and providing appropriate care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening for anxiety and depression)
Number of subjects: 0
Study: 26866766

Group type: EXPERIMENTAL
Intervention: Team games (high physical exertion and high cognitive engagement)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (high physical exertion but low cognitive engagement)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control condition (low physical exertion and low cognitive engagement)
Number of subjects: 181
Study: 21519879

Group type: EXPERIMENTAL
Intervention: Frailty syndrome
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Frailty syndrome in demented patients
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Frailty syndrome in nondemented older subjects
Number of subjects: 2581
Study: 19444237

Group type: EXPERIMENTAL
Intervention: Fortified human milk
Number of subjects: 32

Group type: COMPARATOR
Intervention: Assumed nutrient intakes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 32
Study: 17328806

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate (4 mg/kg/day x 3 d)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Amodiaquine plus placebo (10 mg/kg/day x 3 d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate
Number of subjects: 85

Group type: COMPARATOR
Intervention: Amodiaquine plus placebo
Number of subjects: 85
Study: 15465986

Group type: EXPERIMENTAL
Intervention: Imipramine plus interpersonal psychotherapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Imipramine alone
Number of subjects: 114

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy alone
Number of subjects: 114

Group type: COMPARATOR
Intervention: No active treatment (placebo)
Number of subjects: 114
Study: 11145479

Group type: EXPERIMENTAL
Intervention: Antithrombin treatment (100 U/kg BW during 24 hours)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 9876448

Group type: EXPERIMENTAL
Intervention: Endolymphatic irradiation with lipoiodine containing 131I (specific activity 4-6 mCu/ml)
Number of subjects: 2
Study: 7989902

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (10 ng kg‐1 min‐1) for 1 hour in EH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion during sodium nitroprusside (NP) infusion in EH
Number of subjects: 23
Study: 2596543

Group type: EXPERIMENTAL
Intervention: 0.6-log unit neutral density filter
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1.5-log unit neutral density filter on Humphrey perimeter
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1.0-log unit neutral density filter on Octopus perimeter
Number of subjects: 5
Study: 30280670

Group type: EXPERIMENTAL
Intervention: Iron Bisglycinate Chelate (FeBC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polymaltose Iron (FeP)
Number of subjects: 0
Study: 26922214

Group type: EXPERIMENTAL
Intervention: Composite materials (Biphasic calcium sulphate [BCS] with β Tri‐Calcium Phosphate (β‐TCP) and Hydroxyapatite [HA])
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (natural healing)
Number of subjects: 36
Study: 25399543

Group type: EXPERIMENTAL
Intervention: Medium conditional incentive ($50/six months)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: High conditional incentive ($75/six months)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Unconditional incentive ($50/six months)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study: 22585469

Group type: EXPERIMENTAL
Intervention: Levitan FPS Scope™ (LFS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 94
Study: 19497623

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 0
Study: 17563401

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study: 16274919

Group type: EXPERIMENTAL
Intervention: Older adults walking over obstacles
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increased obstacle height
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Healthy elderly adults negotiating obstacles
Number of subjects: 30
Study: 12421067

Group type: EXPERIMENTAL
Intervention: More frequent syllabic primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonword syllabic primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monosyllabic pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syllables as primes
Number of subjects: 0
Study: 9933789

Group type: EXPERIMENTAL
Intervention: Ultrasound contrast agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-assisted analysis of Doppler signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Doppler ultrasound
Number of subjects: 0
Study: 7729640

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 2188772

Group type: EXPERIMENTAL
Intervention: Benazepril hydrochloride, 5, 10, 20, or 40 mg, once daily for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6771173

Group type: EXPERIMENTAL
Intervention: 15 mg/day of epimestrol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 30888581

Group type: EXPERIMENTAL
Intervention: Cast metal onlay
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indirect resin onlay
Number of subjects: 30
Study: 30560679

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg tablet)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27942207

Group type: EXPERIMENTAL
Intervention: Nordic walking training (12 weeks, three times a week)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 25256368

Group type: EXPERIMENTAL
Intervention: Encouraged group (n = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Discouraged group (n = 27)
Number of subjects: 55
Study: 22422743

Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Number of subjects: 2

Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 2
Study: 20060516

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 0
Study: 18025625

Group type: EXPERIMENTAL
Intervention: 0.5-microg remifentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil and different doses of remifentanil
Number of subjects: 60
Study: 16060911

Group type: EXPERIMENTAL
Intervention: SOM230 250 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SOM230 100 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: OCT 100 microg
Number of subjects: 12
Study: 14607681

Group type: EXPERIMENTAL
Intervention: High concentration glucose intravenously during 24 hours before operation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no glucose treatment)
Number of subjects: 17
Study: 10949727

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (matched)
Number of subjects: 30
Study: 8932889

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1431014

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline or Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 0
Study: 3160273

Group type: EXPERIMENTAL
Intervention: Anticholinergic treatment with ipratropium bromide (Atrovent)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31257642

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) with remote monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard insulin therapy without CGM
Number of subjects: 0
Study: 29166140

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Aflibercept 2 mg
Number of subjects: 76
Study: 26494833

Group type: EXPERIMENTAL
Intervention: Roxadustat (FG-4592)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Roxadustat with oral iron
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Roxadustat with IV iron
Number of subjects: 60

Group type: COMPARATOR
Intervention: No iron
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 60
Study: 24346757

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily for 11 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Duloxetine 60 mg once daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Escitalopram 20 mg/d
Number of subjects: 43
Study: 24160674

Group type: EXPERIMENTAL
Intervention: Text messaging intervention to collect daily alcohol consumption data
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Text delivered intervention on monthly alcohol expenditure
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Text messaging for surveillance and intervention
Number of subjects: 82
Study: 20631210

Group type: EXPERIMENTAL
Intervention: Top‐down selective attention to the affective properties of taste stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top‐down selective attention to the intensity of taste stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention to pleasantness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention to intensity
Number of subjects: 0
Study: 18167173

Group type: EXPERIMENTAL
Intervention: cis-9, trans-11-conjugated linoleic acid (CLA) 2 g/d for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (high-oleic acid sunflower-seed oil)
Number of subjects: 40
Study: 16415704

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/d)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Olanzapine (for nonrelapsing patients)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo (for nonrelapsing patients)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Olanzapine (for nonexacerbating nonrelapsing patients)
Number of subjects: 304
Study: 12784163

Group type: EXPERIMENTAL
Intervention: Elderly athletes with LV hypertrophy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hypertensive patients with LV hypertrophy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy sedentary controls
Number of subjects: 48
Study: 10982347

Group type: EXPERIMENTAL
Intervention: IFN induction (daily) therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IFN plus ribavirin combination therapy
Number of subjects: 20
Study: 8783915

Group type: EXPERIMENTAL
Intervention: Silicone cups
Number of subjects: 72

Group type: COMPARATOR
Intervention: Metal cups
Number of subjects: 72
Study: 1462021

Group type: EXPERIMENTAL
Intervention: Nebulized fenoterol (5 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ipratropium bromide (0.5 mg)
Number of subjects: 9
Study: 31805450

Group type: EXPERIMENTAL
Intervention: Debate on the opt-out system of organ donation
Number of subjects: 13
Study: 30845197

Group type: EXPERIMENTAL
Intervention: Threatening message about the danger of texting while driving
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonthreatening message
Number of subjects: 0
Study: 27746377

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection followed by exercise therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intra-articular saline injection followed by exercise therapy
Number of subjects: 100
Study: 25553751

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 47
Study: 23837414

Group type: EXPERIMENTAL
Intervention: Combination (aromatherapy and hand massage)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Aromatherapy (3% lavender oil spray)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo control (water spray)
Number of subjects: 67
Study: 21825093

Group type: EXPERIMENTAL
Intervention: Jin Shin Jyutsu (JSJ) treatments, 10 weekly sessions
Number of subjects: 29
Study: 19242338

Group type: EXPERIMENTAL
Intervention: NaCl 0.9%, gelatin 4%, hydroxyethyl starch 6%, or albumin 5% loading for 90 minutes
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Colloids
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Colloids and crystalloids
Number of subjects: 48
Study: 17314262

Group type: EXPERIMENTAL
Intervention: Bar on 4 implants
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Bar on 2 implants
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ball attachments on 2 implants
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study: 15567641

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: ropivacaine 0.2%
Number of subjects: 40
Study: 11598845

Group type: EXPERIMENTAL
Intervention: Nevirapine (n=8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Indinavir-based HAART (n=6)
Number of subjects: 14
Study: 9886517

Group type: EXPERIMENTAL
Intervention: LNG rod implants
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Norplant capsules
Number of subjects: 1198
Study: 8027856

Group type: EXPERIMENTAL
Intervention: Calcium plus trace minerals (1000 mg elemental Ca/d, 15.0 mg zinc/d, 5.0 mg manganese/d, 2.5 mg copper/d)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Calcium only (1000 mg elemental Ca/d)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Trace minerals only (15.0 mg zinc/d, 5.0 mg manganese/d, 2.5 mg copper/d)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 2755611

Group type: EXPERIMENTAL
Intervention: Topical application of amniotic membrane
Number of subjects: 0
Study: 30698215

Group type: EXPERIMENTAL
Intervention: thermal mattress
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: underbody forced‐air warming blanket
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: heated infusion system
Number of subjects: 75
Study: 28617537

Group type: EXPERIMENTAL
Intervention: Spirulina (2 g daily for three months)
Number of subjects: 50
Study: 26540973

Group type: EXPERIMENTAL
Intervention: Standard decompress craniectomy and under‐temporal cranioplasty (Group A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Modified cranioplasty with small bone chips and temporal muscle reconstruction (Group B)
Number of subjects: 68
Study: 22676856

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 21410488

Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: General health information about alcohol consumption and fetal alcohol syndrome (Control)
Number of subjects: 150
Study: 19701648

Group type: EXPERIMENTAL
Intervention: Blind women
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sighted women
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sighted women (eyes closed)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isometric and concentric strength measurements
Number of subjects: 20
Study: 17902008

Group type: EXPERIMENTAL
Intervention: Combination of sertraline (25 mg/day for 2 days, then 50 mg from day 3 to 90) and buspirone (5 mg three times a day for 7 days, then 10 mg from day 8 to 90) plus cognitive-behavioral treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo plus cognitive-behavioral treatment
Number of subjects: 98
Study: 14659445

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200 mg disodium clodronate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 200 mg disodium clodronate
Number of subjects: 40
Study: 11310461

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (1 mg/kg) plus intravenous midazolam (0.1 mg/kg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intranasal midazolam (0.4 mg/kg)
Number of subjects: 53
Study: 9135185

Group type: EXPERIMENTAL
Intervention: Rocuronium (twice ED95 dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium (standard dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of rocuronium and vecuronium (equipotent dose)
Number of subjects: 0
Study: 8176144

Group type: EXPERIMENTAL
Intervention: Geriatric Assessment Units (GAUs)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Community-based private physicians (CMDs)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: GAUs
Number of subjects: 364

Group type: COMPARATOR
Intervention: CMDs
Number of subjects: 364
Study: 3163212

Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (HiDAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential asparaginase
Number of subjects: 0
Study: 30654929

Group type: EXPERIMENTAL
Intervention: CTO PCI (n=148)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conservative CTO treatment (n=154)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: SYNTAX score above median
Number of subjects: 302